Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Revolution revamp

How Revolution’s SHP-2 inhibitor persuaded Nextech to back $56 million series B

April 27, 2018 3:05 PM UTC

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round.

Fellow new investors Casdin Capital and Schroder Adveq and existing investors Third Rock Ventures and The Column Group also participated in the round, which closed on April 24. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article